Humanigen Inc.

Humanigen Inc.: Humanigen is developing Lenzilumab, an anti-GM-CSF therapy. Multiple ongoing trials for the treatment of COVID-related ARDS including the ACTIV-5 trial conducted by the NIH. Lenz originally developed to stop cytokine storm in CAR-T patients.
Based in...
US - Pacific
Clinical Stage
Phase III
Disease Space
Anti-inflammatory, COVID-19, Infectious Disease, Oncology
Public, USA
Market Cap
1B +
Therapeutic Modalities
533 Airport Blvd
Suite 400
Burlingame, CA 94010
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Cameron Durrant, MD
Humanigen Inc., Chairman/CEO
Senior pharmaceutical and biotech exec, turnaround specialist Senior exec roles at Pharmacia/Pfizer, J+J in US, Merck, GSK in Europe; experience as Exec Chairman, CEO and CFO; CEO roles at three specialty pharma groups Expertise in anti-infectives, pediatrics, oncology
Richard Brown
Humanigen Inc., Director of Investor Relations
Richard is with Humanigen, serving as Director of Investor Relations.
Timothy Edward Morris
Humanigen Inc., CFO/COO
Mr. Morris served as Chief Financial Officer fro 2014-2020. Previously, Mr. Morris served as a Chief Financial Officer, Senior Vice President Finance and Global Corporate Development of VIVUS, Inc. from November 2004 to December 2013. At VIVUS Mr. Morris oversaw finance, corporate development, IT, human resources, legal, and investor relations functions. Prior to VIVUS, Mr. Morris was CFO, Senior Vice President Finance, Manufacturing and Administration from September 2001 to November 2004, and was a member of the Office of the President from August 2004 to November 2004 for Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development, acquisition, and marketing of pharmaceutical products. Mr. Morris graduated cum laude with a BS in Business with emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant.

Top 10 Holders of Humanigen Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Valiant Capital Management LP 31.02 7,074,220 138.58 13F 9/30/20
Black Horse Capital Management LLC 12.21 2,785,258 54.56 Stakes 9/18/20
VR Adviser LLC 10.23 2,332,516 45.69 13F 9/30/20
The Vanguard Group, Inc. 6.89 1,571,078 30.78 Funds 12/31/20
Think Investments LP 5.87 1,337,808 26.21 13F 9/30/20
Citadel LP 5.77 1,315,891 25.78 13F 9/30/20
Polar Capital LLP 3.62 825,000 16.16 13F 9/30/20
BlackRock Advisors LLC 2.92 665,196 13.03 13F 9/30/20
Point72 Asset Management LP (Old) 2.19 500,000 9.80 13F 9/30/20
Anson Funds Management LP 1.79 408,356 8.00 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.